WebOncology Drug Reference Sheet: Daratumumab. April 28, 2024 by Erin Dickman MS, RN, OCN®. Daratumumab (Darzalex ®) was originally approved by the U.S. Food and Drug Administration in 2015 with additional indications added since. The most recent new indication was approved in September 2024 for newly diagnosed patients with multiple … WebDARZALEX FASPRO ® contains 1,800 mg of daratumumab and 30,000 units of hyaluronidase in a 15 mL solution. Recombinant hyaluronidase increases permeability of …
Treating Myeloma With Darzalex Faspro Int Myeloma Fn
Webproduct with the proprietary name, Darzalex Faspro, and market it in a 1,800 mg (b) (4) (b) (4) (b) (4) daratumumab and 30,000 Units hyaluronidase per 15 mL (120 mg/2,000 Units per mL) Injection in a single-dose vial. DATING PERIOD The dating period for Darzalex Faspro shall be 12 months from the date of manufacture when stored at 2°C to 8°C. WebJul 21, 2024 · DARZALEX ® (daratumumab) is the first monoclonal antibody (mAb) to receive U.S. Food and Drug Administration approval to treat multiple myeloma and has become a backbone therapy in the treatment... small battery jumpers portable
Darzalex/Darzalex Faspro Drug Information The MMRF
WebDARZALEX FASPRO® ®(daratumumab and hyaluronidase- hj) injection DARZALEX FASPRO (daratumumab and hyaluronidase- hj) injection 2 FULL PRESCRIBING … WebApr 3, 2024 · CONTRAINDICATIONS. DARZALEX FASPRO ® is contraindicated in patients with a history of severe hypersensitivity to daratumumab, hyaluronidase, or any of the components of the formulation.. WARNINGS AND PRECAUTIONS. Hypersensitivity and Other Administration Reactions. Both systemic administration-related reactions, including … WebMay 1, 2024 · Darzalex Faspro in combination with bortezomib, cyclophosphamide and dexamethasone is indicated for the treatment of … solo battery powered backpack sprayer nz